Aaron Goldman

Aaron Goldman

Auto-generated profile, based on publicly available information

Aaron Goldman

Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
AGAaron Goldman
Aaron Goldman
BMBiswanath Majumder
Biswanath Majumder
ADAndrew Dhawan
Andrew Dhawan
SRSudharshan Ravi
Sudharshan Ravi
DGDavid Goldman
David Goldman
SSShiladitya Sengupta
Shiladitya Sengupta
Understanding the emerging models of adaptive resistance is key to overcoming cancer chemotherapy failure. Using human breast cancer explants, in vitro cell lines, mouse in vivo studies and mathematical modelling, here we show that exposure to a taxane induces phenotypic cell state transition towards a favoured transient CD44HiCD24Hi chemotherapy-tolerant state. This state is associated with a clustering of CD44 and CD24 in membrane lipid rafts, leading to the activation of Src Family Kinase (SFK)/hemopoietic cell kinase (Hck) and suppression of apoptosis. The use of pharmacological inhibitors of SFK/Hck in combination with taxanes in a temporally constrained manner, where the kinase inhibitor is administered post taxane treatment, but not when co-administered, markedly sensitizes the chemotolerant cells to the chemotherapy. This approach of harnessing chemotherapy-induced phenotypic cell state transition for improving antitumour outcome could emerge as a translational strategy for the management of cancer.

1 February 2022 in Drug Discovery Today
Verified
Journal Article
Open access
SMSepideh Mirzaei
Sepideh Mirzaei
MGMohammad Hossein Gholami
Mohammad Hossein Gholami
FHFarid Hashemi
Farid Hashemi
AZAmirhossein Zabolian
Amirhossein Zabolian
MFMahdi Vasheghani Farahani
Mahdi Vasheghani Farahani
GOGorka Orive
Gorka Orive
P-glycoprotein (P-gp) is a drug efflux transporter that triggers doxorubicin (DOX) resistance. In this review, we highlight the molecular avenues regulating P-gp, such as Nrf2, HIF-1α, miRNAs, and long noncoding (lnc)RNAs, to reveal their participation in DOX resistance. These antitumor compounds and genetic tools synergistically reduce P-gp expression. Furthermore, ATP depletion impairs P-gp activity to enhance the antitumor activity of DOX. Nanoarchitectures, including liposomes, micelles, polymeric nanoparticles (NPs), and solid lipid nanocarriers, have been developed for the co-delivery of DOX with anticancer compounds and genes enhancing DOX cytotoxicity. Surface modification of nanocarriers, for instance with hyaluronic acid (HA), can promote selectivity toward cancer cells. We discuss these aspects with a focus on P-gp expression and activity.

20 August 2019 in Science Signaling
Verified
Journal Article
Closed access
PDF file
AGAaron Goldman
Aaron Goldman
SKSachin Khiste
Sachin Khiste
EFElizaveta Freinkman
Elizaveta Freinkman
ADAndrew Dhawan
Andrew Dhawan
BMBiswanath Majumder
Biswanath Majumder
SSShiladitya Sengupta
Shiladitya Sengupta
Metastable phenotypic state transitions in cancer cells can lead to the development of transient adaptive resistance or tolerance to chemotherapy. Here, we report that the acquisition of a phenotype marked by increased abundance of CD44 (CD44Hi) by breast cancer cells as a tolerance response to routinely used cytotoxic drugs, such as taxanes, activated a metabolic switch that conferred tolerance against unrelated standard-of-care chemotherapeutic agents, such as anthracyclines. We characterized the sequence of molecular events that connected the induced CD44Hi phenotype to increased activity of both the glycolytic and oxidative pathways and glucose flux through the pentose phosphate pathway (PPP). When given in a specific order, a combination of taxanes, anthracyclines, and inhibitors of glucose-6-phosphate dehydrogenase (G6PD), an enzyme involved in glucose metabolism, improved survival in mouse models of breast cancer. The same sequence of the three-drug combination reduced the viability of patient breast tumor samples in an explant system. Our findings highlight a convergence between phenotypic and metabolic state transitions that confers a survival advantage to cancer cells against clinically used drug combinations. Pharmacologically targeting this convergence could overcome cross-drug tolerance and could emerge as a new paradigm in the treatment of cancer.

5 November 2020 in Chemical Reviews
Verified
Journal Article
Closed access
MCMorgan Craig
Morgan Craig
AJAdrianne L. Jenner
Adrianne L. Jenner
BNBumseok Namgung
Bumseok Namgung
LLLuke P. Lee
Luke P. Lee
AGAaron Goldman
Aaron Goldman

7 February 2018 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
NKNaveen Kumar
Naveen Kumar
PPPeeyush Prasad
Peeyush Prasad
EJEshna Jash
Eshna Jash
MSMegha Saini
Megha Saini
AHAmjad Husain
Amjad Husain
SSSeema Sehrawat
Seema Sehrawat

26 August 2019 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
MCMorgan Craig
Morgan Craig
KKKamran Kaveh
Kamran Kaveh
AWAlec Woosley
Alec Woosley
ABAndrew S. Brown
Andrew S. Brown
DGDavid Goldman
David Goldman
AGAaron Goldman
Aaron Goldman
Understanding intrinsic and acquired resistance is crucial to overcoming cancer chemotherapy failure. While it is well-established that intratumor, subclonal genetic and phenotypic heterogeneity significantly contribute to resistance, it is not fully understood how tumor sub-clones interact with each other to withstand therapy pressure. Here, we report a previously unrecognized behavior in heterogeneous tumors: cooperative adaptation to therapy (CAT), in which cancer cells induce co-resistant phenotypes in neighboring cancer cells when exposed to cancer therapy. Using a CRISPR/Cas9 toolkit we engineered phenotypically diverse non-small cell lung cancer (NSCLC) cells by conferring mutations in Dicer1, a type III cytoplasmic endoribonuclease involved in small non-coding RNA genesis. We monitored three-dimensional growth dynamics of fluorescently-labeled mutant and/or wild-type cells individually or in co-culture using a substrate-free NanoCulture system under unstimulated or drug pressure conditions. By integrating mathematical modeling with flow cytometry, we characterized the growth patterns of mono- and co-cultures using a mathematical model of intra- and interspecies competition. Leveraging the flow cytometry data, we estimated the model’s parameters to reveal that the combination of WT and mutants in co-cultures allowed for beneficial growth in previously drug sensitive cells despite drug pressure via induction of cell state transitions described by a cooperative game theoretic change in the fitness values. Finally, we used an ex vivo human tumor model that predicts clinical response through drug sensitivity analyses and determined that cellular and morphologic heterogeneity correlates to prognostic failure of multiple clinically-approved and off-label drugs in individual NSCLC patient samples. Together, these findings present a new paradox in drug resistance implicating non-genetic cooperation among tumor cells to thwart drug pressure, suggesting that profiling for druggable targets (i.e. mutations) alone may be insufficient to assign effective therapy. Here, we provide mathematical and empirical evidence to support a potentially new paradigm in drug resistance, which we have termed “cooperative adaptation to therapy” (CAT). CAT is defined by a phenomenon wherein drug-sensitive cancer cells with different genetic and phenotypic features within a 3-dimensional heterogeneous tumor induce non-mutational resistance in their neighboring cells under pressure of cancer therapy. To develop this novel conclusion we deployed an interdisciplinary effort including an ex vivo human tumor model, a CRISPR/Cas9 platform with 3-dimensional in vitro experiments, and high throughput flow cytometry. Importantly, we wove these data together using a mathematical model of intra- and interspecies competition to understand how tumor heterogeneity influenced our observations. By estimating the model’s parameters, we determined that the combination of genetic clonal variants in co-cultures allowed for previously drug-sensitive cells to continue to grow despite drug pressure. We were thus able to characterize distinct growth regimens in mono- and co-cultures without and with drug pressure.